Question 1

What does Keros Therapeutics do in rare disease treatment?

Accepted Answer

Keros Therapeutics is a clinical-stage biopharmaceutical company developing therapies for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-beta) family of proteins. The company's lead product candidate, rinvatercept, is in development for Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its most advanced product candidate, elritercept (KER-050), is in development for cytopenias including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis, and is partnered with Takeda. Keros discontinued its PAH program (cibotercept/KER-012) in May 2025 following the failed TROPOS Phase 2 trial.

Question 2

What rare diseases does Keros Therapeutics focus on?

Accepted Answer

Keros Therapeutics has active programs across 3 rare diseases: Duchenne Muscular Dystrophy, Myelofibrosis, Pulmonary Arterial Hypertension. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.

Question 3

Is Keros Therapeutics focused exclusively on rare diseases?

Accepted Answer

Yes. Keros Therapeutics is a rare disease specialist headquartered in Lexington, United States, founded in 2015. The company focuses primarily on developing treatments for rare and orphan diseases, with programs targeting Duchenne Muscular Dystrophy, Myelofibrosis, Pulmonary Arterial Hypertension.

Question 4

How can I find Keros Therapeutics clinical trials for rare diseases?

Accepted Answer

This page shows all active and recruiting clinical trials sponsored by Keros Therapeutics, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.

Question 5

How do I enroll in a Keros Therapeutics clinical trial?

Accepted Answer

To explore enrollment, find a recruiting trial on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.

Question 6

What FDA-approved rare disease drugs does Keros Therapeutics have?

Accepted Answer

The FDA-Approved Drugs section on this page lists all Keros Therapeutics drugs with FDA approval that are relevant to rare diseases, including brand names, generic names, approval dates, and the rare conditions each drug treats. This data comes from the FDA's openFDA database and is updated automatically.

Question 7

When was Keros Therapeutics founded and where is it based?

Accepted Answer

Keros Therapeutics was founded in 2015 and is headquartered in Lexington, United States. The company has been active for 11 years. It trades publicly under the ticker symbol KROS. As a rare disease specialist, the company dedicates its resources to developing therapies for patients with rare and orphan conditions.

Keros Therapeutics

Active Clinical Trials

FDA-Approved Drugs

Rare Disease Focus Areas (3)

Patient Resources

Frequently Asked Questions About Keros Therapeutics

Active Clinical Trials

FDA-Approved Drugs

Rare Disease Focus Areas (3)

Related Companies

Patient Resources

Frequently Asked Questions About Keros Therapeutics